Login
$AEON
$0.15 +$0.01 (7.46%) After hours

Company Executives

Officer Age In this role Joined Source
Robert Bancroft Also a director
President, Chief Executive Officer and Director
61 Not stated Not stated
John Bencich
Chief Financial Officer
49 Since 2026
this year
Not stated
Chad Oh
Chief Medical Officer
68 Since 2021
5 years
Not stated
Alex Wilson
Chief Legal & Strategy Officer; Corporate Secretary
40 Not stated 2021
Jennifer Sy
Chief Accounting Officer
41 Since 2025
1 year
Not stated

Each officer opens the passage of the filing that names them. A title that changed since the list comes from the officer's latest Form 3, 4 or 5, and its start year is not stated there. "Not stated" means the filing does not say. Pay is the proxy's Summary Compensation Table, which reports only the named executive officers.

Directors
7
serving now
Independent
4 of 4
stated in the proxy; 3 not stated
Average tenure
3.4 years
from year joined
CEO also chairs the board
No
Jost Fischer
Director Age On board Independent Committees Other public boards 2025 pay Source
Jost Fischer
71 2017
9 years
Independent
Audit Committee Compensation Committee · Chair
None stated $237,500
Robert Bancroft
61 2025
1 year
Not stated None stated None stated Paid as CEO
Marc Forth
55 2023
3 years
Not stated None stated None stated $213,250
Seongsoo Park
50 2024
2 years
Not stated None stated None stated Not stated
Robert Palmisano
81 2023
3 years
Independent
Compensation Committee Nominating & Corporate Governance Committee · Chair
None stated $207,500
Shelley Thunen
73 2023
3 years
Independent
Audit Committee · Chair
LENZ Therapeutics $212,500
Eric Carter, Ph.D., M.D.
74 2023
3 years
Independent
Audit Committee Compensation Committee
None stated Not stated

Each director opens the passage of the proxy that names them. "Not stated" means the proxy does not say; it never means "no". Pay is the proxy's Director Compensation table; the CEO is paid as an executive.

7 disclosed in the proxy filed Apr 29, 2026
Daewoong Pharmaceutical Co., LTD.
Up to $15.0 million
2024

Subscription agreement for sale and issuance of senior secured convertible notes of up to $15.0 million, convertible into common stock

With AEON Biopharma Sub, Inc. Open in proxy
Daewoong Pharmaceutical Co., LTD.
$5,000,000
2024

Initial Closing: Company issued and sold to Daewoong a Convertible Note in the principal amount of $5,000,000

With Company Open in proxy
Daewoong Pharmaceutical Co., LTD.
$10,000,000
2024

Subsequent Closing: Company issued and sold to Daewoong a second Convertible Note in the principal amount of $10,000,000

With Company Open in proxy
Daewoong Pharmaceutical Co., LTD.
Amount not stated
2025

Exchange of Convertible Notes held by Daewoong for exchange shares, a new senior secured convertible note for $1.5 million, and warrants to purchase up to 8 million shares

With Company Open in proxy
Seongsoo Park
Daewoong designee to serve as a Class III director
Amount not stated

Company to nominate a Daewoong designee to the board; the designee is currently Seongsoo Park, who serves on the board

With Company Open in proxy
Daewoong Pharmaceutical Co., LTD.
Amount not stated
2024

Fourth Amendment to the License and Supply Agreement, including termination and a $1.00 Know-How purchase right for Daewoong

With AEON Open in proxy
Daewoong Pharmaceutical Co., LTD.
Amount not stated
2026

Fifth Amendment to the License and Supply Agreement entered in connection with the Exchange

With Company Open in proxy

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support